Biology:Companion diagnostic

From HandWiki
Jump to: navigation, search
Companion diagnostic
Medical diagnostics
Purposeto determine the correct therapeutic agent for an individual

A companion diagnostic (CDx)[1] is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.[2]

Companion diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.[3][4]

Companion diagnostics are developed based on companion biomarkers, biomarkers that prospectively help predict likely response or severe toxicity.[5]

See also

References

  1. "Pfizer Taps Foundation Medicine for CDx Development". Clinical OMICs. 16 January 2018. https://www.clinicalomics.com/articles/cancer-cdx-collaboration-brings-foundation-medicine-and-pfizer-together/1433. 
  2. "Companion Diagnostics" (Page Last Updated 07/14/2016). FDA. https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407297.htm. Retrieved 26 September 2016. 
  3. Trusheim, MR; Burgess, B; Hu, SX; Long, T; Averbuch, SD; Flynn, AA; Lieftucht, A; Mazumder, A et al. (31 October 2011). "Quantifying factors for the success of stratified medicine.". Nature Reviews. Drug Discovery 10 (11): 817–33. doi:10.1038/nrd3557. PMID 22037040. 
  4. Kim, Il-Jin (2019-03-06) (in en). Companion Diagnostics (CDx) in Precision Medicine. CRC Press. ISBN 978-1-000-00721-3. https://books.google.com.eg/books?id=wuOLDwAAQBAJ&pg=PT144&dq=Companion+diagnostic&hl=en&sa=X&ved=0ahUKEwjPnt__tP_pAhW5ShUIHeNABboQ6AEIJzAA. 
  5. Duffy, MJ; Crown, J (October 2013). "Companion biomarkers: paving the pathway to personalized treatment for cancer.". Clinical Chemistry 59 (10): 1447–56. doi:10.1373/clinchem.2012.200477. PMID 23656699. http://clinchem.aaccjnls.org/content/59/10/1447.long.